<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230727058942N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-18</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>comparison between masport and dysport in facial botox</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects and side effects of Dysport and Masport in patients referred to the ultra-specialized oculoplasty clinic of Farabi Hospital in 1402</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-27</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72114</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is performed using a stratified permuted block randomization method with random block lengths (2, 4, 6). After screening, patients will be randomly assigned to groups A and B in a 1:1 ratio to receive Dysport or Masport injections. Stratification variables, including age and gender, will be determined as follows:

ARMS (RATIOS: 1:1):
* A
* B

STRATIFY: Yes

TOTAL STRATA: 4

STRATIFICATION VARIABLES:
1) Sex: 
   * male
   * female
2) age: 
   * &lt;40
   * &gt;40

For this purpose, a randomization program was written in R software with the help of the center's biostatistician, and the randomization output was produced as an Excel file. Patients, researchers, and site personnel (except pharmacists) are blinded to the type of injectable drug and will remain so until the end of the follow-up period and analysis of the study data, Blinding description: In this study, which is a kind of double-blind study, all participating patients and doctors involved, including the relevant professor who is responsible for the injection and the relevant resident who is responsible for coordinating and writing articles and theses, as well as the nurse related to The design is all kept blind during the design and it is an injectable drug type
(Mesport or Dysport brand) do not know. Injection vials are prepared in completely identical and similar syringes by the relevant person and brought to the hospital.</study_design>
      <phase>3</phase>
      <hc_freetext>Investigating the therapeutic effects of two drugs, MASPORT and DYSPORT, on wrinkles around the eyes. forehead.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group 1: under MASPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is manufactured by Masoun Daru pharmaceutical company with the permission of the Ministry of Health in Iran. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unmarked vial for the validity of randomization, and in each person, 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with a syringe. In this study, 1 injection was performed. Intervention 2: Control group: intervention group 2: they are subjected to DYSPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is available in the country under the brand name DYSPORT with the official license of the Ministry of Health as an import made in Italy or France. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unspecified vial for the validity of randomization, and 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with an insulin syringe. In this study, 1 injection was performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ghazal ghochani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi Ophthalmology Hospital, Qazvin Square, Tehran</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>136616351</zip>
        <telephone>+98 21 5540 0003</telephone>
        <email>Gghochani@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ghazal Ghochani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi Ophthalmology Hospital, Qazvin Square, Tehran</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>136616351</zip>
        <telephone>+98 21 5540 0003</telephone>
        <email>Gghochani@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Physical and mental health
The ability to make decisions regarding voluntary participation in the study
Permissible age range in study (27-54 years old)
Botox injection candidate in the studied areas</inclusion_criteria>
      <agemin>27 years</agemin>
      <agemax>57 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of heavy surgeries and any type of fracture in any part of the face
History of stroke and facial paralysis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H00-H06</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>بررسی اختلالات کاسه چشم و پلک ها</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group 1: under MASPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is manufactured by Masoun Daru pharmaceutical company with the permission of the Ministry of Health in Iran. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unmarked vial for the validity of randomization, and in each person, 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with a syringe. In this study, 1 injection was performed.</i_keyword>
      <i_keyword>Control group: intervention group 2: they are subjected to DYSPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is available in the country under the brand name DYSPORT with the official license of the Ministry of Health as an import made in Italy or France. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unspecified vial for the validity of randomization, and 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with an insulin syringe. In this study, 1 injection was performed</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1- To investigate the effect of two drugs in the same doses in removing and reducing the depth of wrinkles in patients. Timepoint: At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection. Method of measurement: A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.</prim_outcome>
      <prim_outcome>2- Examining the short-acting and long-acting side effects of both drugs, including inflammation, redness, and drooping of the eyelids. Timepoint: At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection. Method of measurement: A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.</prim_outcome>
      <prim_outcome>3- Checking the shelf life of two drugs. Timepoint: At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection. Method of measurement: A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.</prim_outcome>
      <prim_outcome>4- Checking the need for re-injection and restoration of two drugs at intervals of 2 weeks, 2 months and 4 months. Timepoint: At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection. Method of measurement: A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Masoun Daro Company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-22</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Farabi Ophthalmology Hospital, Qazvin Square, Tehran tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
